



# Travel Conundrums

**Sheila Mackell, MD, CTH, CTropMed, FISTM**  
**Pediatrics & Travel Medicine**  
**Flagstaff, AZ**

**AZDHS IMMUNIZATION CONFERENCE**  
**4/24/2024**





**I have no conflicts to declare**





# Learning Objectives

- **Review the challenges and conundrums of travel vaccines using case studies.**
- **Examine travel recommendations for a variety of travel itineraries and ages using a case oriented approach.**
- **Review pre-travel measures to mitigate common threats to travelers in the developing world.**
- **Discuss challenging travel scenarios-children, pregnancy, immune compromise**






- **Case 1 - traveling children**
- **Case 2 - pregnant traveler**
- **Case 3 - immunocompromised traveler**
  
- **More depending on timing...**

# What's new.. From CISTM18

- **Climate change impact on travel**
- **A few new vaccines/indications**
  - Malaria (Ghana, Kenya, Malawi pilot roll out)
  - Cholera , Dengue
  - Chikungunya- recently approved
- **More Dengue, West Nile Virus and tick infections**
- **A new Yellow Book to explore**
  - Highly allergic traveler
  - Medical tourism
  - LGBTQ+ traveler





# New 'travel related' vaccines

- Cholera
- Dengue
- Malaria (Ghana, Kenya, Malawi pilot roll out)
- Chikungunya- approved 2/24
- TBE



# Cholera vaccine

- Single dose live attenuated oral vaccine (CVD 103-HgR)
- Recommended for ages 2-64 yrs to areas with **active cholera transmission**
- Duration of protection beyond 3 months not studied
- Avoid concurrent chloroquine and oral typhoid vaccine

MMWR 2022




# Current areas of active cholera transmission

- ▶ **Africa: Burundi, Cameroon, Comoros, Democratic Republic of the Congo, Ethiopia, Kenya, Malawi, Mozambique, Nigeria, Republic of the Congo, Somalia, South Africa, Sudan, South Sudan, Uganda, Tanzania, Zambia, Zimbabwe**
- ▶ **Asia: Afghanistan, Bangladesh, India, Pakistan, Philippines**
- ▶ **Middle East: Iraq, Lebanon, Syria, Yemen**
- ▶ **Americas: Dominican Republic, Haiti**
- ▶ **Pacific: none**

**\*\* Check the CDC destination page for details on whether vaccination should be considered**







# Dengue Vaccine


- **Sanofi-Pasteur vaccine (Dengvaxia)**
- **2019 approval, limited indications- **not** for travelers**
- **9 -16 yr olds with history of lab-confirmed dengue infection**
- **Other products in phase 3 trials - stay tuned**
- **Insect bite avoidance measures !**






# Chikungunya

- **Arboviral infection similar to dengue, but with often severe post-infectious arthritis/arthralgia**
- **Vaccine 2/24**
  - **>18 yo**
  - **Travel to outbreak area**
  - **Long stay (>6 mo) in transmission area**
  - **>65 yo , with underlying conditions and moderate exposure**
- **Insect bite avoidance**



# Mpox vaccine

- **Intradermal or Subcutaneous administration**
- **Any person at risk: 2-dose series, 28 days apart**
- **Outbreak in DRC currently**





# Mpox vaccine

## Mpox vaccination

### Special situations

- **Any person at risk for Mpox infection:** 2-dose series, 28 days apart.

#### Risk factors for Mpox infection include:

- Persons who are gay, bisexual, and other MSM, transgender or nonbinary people who in the past 6 months have had:
  - A new diagnosis of at least 1 sexually transmitted disease
  - More than 1 sex partner
  - Sex at a commercial sex venue
  - Sex in association with a large public event in a geographic area where Mpox transmission is occurring
- Persons who are sexual partners of the persons described above
- Persons who anticipate experiencing any of the situations described above



- **Pregnancy:** There is currently no ACIP recommendation for Jynneos use in pregnancy due to lack of safety data in pregnant persons. Pregnant persons with any risk factor described above may receive Jynneos.
- **Healthcare personnel:** Except in rare circumstances (e.g. no available personal protective equipment), healthcare personnel who do not have any of the sexual risk factors described above should not receive Jynneos.

For detailed information, see: [www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-10-25-26/04-MPOX-Rao-508.pdf](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-10-25-26/04-MPOX-Rao-508.pdf)



# Special populations

- Immunocompromised
- Visiting friends and relatives (VFR)
- Seeking health services (transplants, dental, cosmetic surgery)
- Adventure/extreme travel
- Older adult
- Young children
- Students
- Long-stay
- Relief workers





# Travel Vaccines and overall consult goals

## Immunization

Routine

Required (WHO regulated)

Recommended, itinerary based

## Malaria Chemoprophylaxis and Bite Prevention

Medication choice/delivery/cost/availability/SE

Repellents, nets, clothing barriers

## Traveler's Diarrhea Prevention and management

## Travel-related health risks

Accidents    Medical/evac insurance

Animal bites


Sunburn, swimming



# Case 1

**A family of 2 healthy children is going to visit relatives in Ghana for the summer.**

- **Ages 5 mos, 4 yrs old**
- **5 mo old is breastfeeding**
- **No allergies**



**The oldest has been there 2 years ago and was hospitalized for severe diarrhea. Parents are anxious about the children getting sick there.**



## What vaccines would be appropriate for this 5 month old?

0

A Yellow Fever

0%

B MMR

0%

C Typhoid

0%

D DTaP-IPV-HepB

0%

E Rabies

0%

None of the above

0%

# Vaccinating the child traveler

- **Routine vaccines**  
accelerate as needed  
update
- **Required**
- **Recommended**



## Birth to 15 Months

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2).

|  | Birth  | 1 mo                     | 2 mos                           | 4 mos   | 6 mos   | 9 mos | 12 mos | 15 mos   |
|--|--|--------------------------|---------------------------------|---|---|-------|--------|--|
| <b>Respiratory syncytial virus</b> ⓘ<br>(RSV-mAb [Nirsevimab])             | 1 dose depending on maternal RSV vaccination status, See <a href="#">notes</a> |                          |                                 |   | 1 dose (8 through 19 months), See <a href="#">notes</a> |       |        |  |
| <b>Hepatitis B</b> ⓘ<br>(HepB)   | 1 <sup>st</sup> dose   | → 2 <sup>nd</sup> dose → |                                 | → 3 <sup>rd</sup> dose →  |   |       |        |  |
| <b>Rotavirus (RV)</b> ⓘ<br>RV1 (2-dose series); RV5 (3-dose series)        |  |                          | 1 <sup>st</sup> dose            | 2 <sup>nd</sup> dose  | See <a href="#">notes</a>                               |       |        |  |
| <b>Diphtheria, tetanus, &amp; acellular pertussis</b> ⓘ<br>(DTaP: <7 yrs)  |  |                          | 1 <sup>st</sup> dose            | 2 <sup>nd</sup> dose  | 3 <sup>rd</sup> dose                                    |       |        | → 4 <sup>th</sup> dose →   |
| <b>Haemophilus influenzae type b</b> ⓘ<br>(Hib)                            |  |                          | 1 <sup>st</sup> dose            | 2 <sup>nd</sup> dose  | See <a href="#">notes</a>                               |       |        | → 3 <sup>rd</sup> or 4 <sup>th</sup> dose, See <a href="#">notes</a> → |
| <b>Pneumococcal conjugate</b> ⓘ<br>(PCV15, PCV20)                          |  |                          | 1 <sup>st</sup> dose            | 2 <sup>nd</sup> dose  | 3 <sup>rd</sup> dose                                    |       |        | → 4 <sup>th</sup> dose →   |
| <b>Inactivated poliovirus</b> ⓘ<br>(IPV: <18 yrs)                          |  |                          | 1 <sup>st</sup> dose            | 2 <sup>nd</sup> dose  | → 3 <sup>rd</sup> dose →                                |       |        |  |
| <b>COVID-19</b> ⓘ<br>(1vCOV-mRNA, 1vCOV-aPS)                               |  |                          |                                 | 1 or more doses of updated (2023–2024 Formula) vaccine (See <a href="#">notes</a> ) |   |       |        |  |
| <b>Influenza (IIV4)</b> ⓘ  |  |                          | Annual vaccination 1 or 2 doses |   |   |       |        |  |
| <b>Influenza (LAIV4)</b> ⓘ   |  |                          |                                 |   |   |       |        | Annual vaccination 1 or 2 doses  |
| <b>Measles, mumps, rubella</b> ⓘ<br>(MMR)                                  |  |                          |                                 |   | See <a href="#">notes</a>                               |       |        | → 1 <sup>st</sup> dose →   |
| <b>Varicella</b> ⓘ<br>(VAR)  |  |                          |                                 |   |   |       |        | → 1 <sup>st</sup> dose →   |
| <b>Hepatitis A</b> ⓘ<br>(HepA)   |  |                          |                                 |   | (See <a href="#">notes</a> )                            |       |        | → 2-dose series, See <a href="#">notes</a> →                           |
| <b>Tetanus, diphtheria, &amp; acellular pertussis</b> ⓘ<br>(Tdap: ≥ 7 yrs) |  |                          |                                 |   |   |       |        |  |
| <b>Human papillomavirus</b> ⓘ<br>(HPV)                                     |  |                          |                                 |   |   |       |        |  |
| <b>Meningococcal</b> ⓘ<br>(MenACWY-CRM ≥ 2 mos, MenACWY-TT ≥ 2years)       |  |                          |                                 |   | See <a href="#">notes</a>                               |       |        |  |
| <b>Meningococcal B</b> ⓘ<br>(MenB-4C, MenB-FHbp)                           |  |                          |                                 |   |   |       |        | See <a href="#">notes</a>  |
| <b>Respiratory syncytial virus vaccine</b> ⓘ<br>(RSV [Abrysvo])            |  |                          |                                 |   |   |       |        | Seasonal administration during pregnancy, See <a href="#">notes</a>    |
| <b>Vaccine and other immunizing agents</b>                                 | Birth  | 1 mo                     | 2 mos                           | 4 mos   | 6 mos   | 9 mos | 12 mos | 15 mos   |
| <b>Dengue</b> ⓘ<br>(DEN4CYD: 9-16 yrs)                                     |  |                          |                                 |   |   |       |        | Seropositive in endemic dengue areas (See <a href="#">notes</a> )      |
| <b>Mpox</b> ⓘ  |  |                          |                                 |   |   |       |        |  |

## 18 Months to 18 Years

|  | 18 mos  | 19-23 mos | 2-3 yrs                         | 4-6 yrs              | 7-10 yrs                       | 11-12 yrs   | 13-15 yrs | 16 yrs               | 17-18 yrs                 |
|--|---|-----------|---------------------------------|----------------------|--------------------------------|---|-----------|----------------------|---------------------------|
| <b>Respiratory syncytial virus</b> ⓘ<br>(RSV-mAb [Nirsevimab])             | 1 dose (8 through 19 months), See <a href="#">notes</a>                             |           |                                 |                      |                                |   |           |                      |                           |
| <b>Hepatitis B</b> ⓘ<br>(HepB)   | → 3 <sup>rd</sup> dose →  |           |                                 |                      |                                |   |           |                      |                           |
| <b>Rotavirus</b> ⓘ<br>(RV) RV1 (2-dose series); RV5 (3-dose series)        |   |           |                                 |                      |                                |   |           |                      |                           |
| <b>Diphtheria, tetanus, &amp; acellular pertussis</b> ⓘ<br>(DTaP: <7 yrs)  | → 4 <sup>th</sup> dose →  |           |                                 | 5 <sup>th</sup> dose |                                |   |           |                      |                           |
| <b>Haemophilus influenzae type b</b> ⓘ<br>(Hib)                            |   |           |                                 |                      |                                |   |           |                      |                           |
| <b>Pneumococcal conjugate</b> ⓘ<br>(PCV15, PCV20)                          |   |           |                                 |                      |                                |   |           |                      |                           |
| <b>Inactivated poliovirus</b> ⓘ<br>(IPV: <18 yrs)                          | → 3 <sup>rd</sup> dose →  |           |                                 | 4 <sup>th</sup> dose |                                |   |           |                      | See <a href="#">notes</a> |
| <b>COVID-19</b> ⓘ<br>(1vCOV-mRNA, 1vCOV-aPS)                               | 1 or more doses of updated (2023–2024 Formula) vaccine (See <a href="#">notes</a> ) |           |                                 |                      |                                |   |           |                      |                           |
| <b>Influenza (IIV4)</b> ⓘ  | Annual vaccination 1 or 2 doses   |           |                                 |                      | Annual vaccination 1 dose only |   |           |                      |                           |
| <b>Influenza (LAIV4)</b> ⓘ   |   |           | Annual vaccination 1 or 2 doses |                      | Annual vaccination 1 dose only |   |           |                      |                           |
| <b>Vaccine and other immunizing agents</b>                                 | 18 mos  | 19-23 mos | 2-3 yrs                         | 4-6 yrs              | 7-10 yrs                       | 11-12 yrs   | 13-15 yrs | 16 yrs               | 17-18 yrs                 |
| <b>Varicella</b> ⓘ<br>(VAR)  |   |           |                                 | 2 <sup>nd</sup> dose |                                |   |           |                      |                           |
| <b>Hepatitis A</b> ⓘ<br>(HepA)   | → 2-dose series, See <a href="#">notes</a> →  |           |                                 |                      |                                |   |           |                      |                           |
| <b>Tetanus, diphtheria, &amp; acellular pertussis</b> ⓘ<br>(Tdap: ≥ 7 yrs) |   |           |                                 |                      |                                | 1 dose  |           |                      |                           |
| <b>Human papillomavirus</b> ⓘ<br>(HPV)                                     |   |           |                                 |                      |                                | See <a href="#">notes</a>   |           |                      |                           |
| <b>Meningococcal</b> ⓘ<br>(MenACWY-CRM ≥ 2 mos, MenACWY-TT ≥ 2years)       | See <a href="#">notes</a>   |           |                                 |                      |                                | 1 <sup>st</sup> dose  |           | 2 <sup>nd</sup> dose |                           |
| <b>Meningococcal B</b> ⓘ<br>(MenB-4C, MenB-FHbp)                           |   |           |                                 |                      |                                | See <a href="#">notes</a>   |           |                      |                           |
| <b>Respiratory syncytial virus vaccine</b> ⓘ<br>(RSV [Abrysvo])            |   |           |                                 |                      |                                | Seasonal administration during pregnancy, See <a href="#">notes</a> |           |                      |                           |
| <b>Dengue</b> ⓘ<br>(DEN4CYD: 9-16 yrs)                                     |   |           |                                 |                      |                                | Seropositive in endemic dengue areas (See <a href="#">notes</a> )   |           |                      |                           |
| <b>Mpox</b> ⓘ  |   |           |                                 |                      |                                |   |           |                      |                           |



# Minimum ages- U.S.

- **Yellow fever - 9 months**
- **Hepatitis A - 6 mo**
- **Typhoid**
  - injectable - 2 yrs
  - oral - 6yrs
- **Rabies - no minimum**
- **Meningococcal meningitis - 2 mo**
- **Japanese encephalitis - 2 mo**
- **Influenza - 6 months**
- **COVID-19 - 6 months**



# Accelerating routine vaccines

|                      | <u>AGE</u>  | <u>MIN INTERVAL</u> |
|----------------------|---|---------------------|
| <b>DTaP&amp;IPV</b>  | <b>6 wks</b>  | <b>4 wks</b>        |
| <b>Hib&amp;PCV15</b> | <b>6 wks</b>  | <b>4 wks</b>        |
| <b>Rotavirus</b>     | <b>6 wks</b>  | <b>4 wks</b>        |
| <b>HepB</b>          | <b>birth</b>  | <b>4 wks</b>        |
| <b>COVID-19</b>      | <b>6 months</b>   | <b>4 wks</b>        |
| <b>MMR</b>           | <b>6-11 mo, repeat at 12 mo old, plus one more dose</b>           |                     |
| <b>Hep A</b>         | <b>6 mo, then 2 dose series at 12 mo or 6 mo after early dose</b> |                     |



# YELLOW FEVER


Mosquito borne viral hemorrhagic disease

Countries at risk: 34 in Africa & 13 in Central/S Am

Infant imz programs in 36 of 40 endemic countries

Estimated infant coverage 47%

Mass vaccination campaigns ongoing





# YELLOW FEVER VACCINE

**Live attenuated** viral vaccine, regulated by IHR

**Egg based**

**Age related risk of post-vaccine encephalitis**

**Contraindicated** : <6 mo olds ; Egg allergy ; certain thymus disorders; primary immunodeficiencies/ Symptomatic HIV; malignant neoplasms, organ transplantation, immunosuppressive & immunomodulatory therapies

**Caution** : age > 60 yo ;Asymptomatic HIV infection (with caveats); pregnancy; breastfeeding

# Yellow Fever Vaccine

## Age related risk of post-vaccine encephalitis

### Age

<6 mos.

6-9 mos.

>9 mos.

### Recommendation

**NEVER**

**CDC consult**

**Same as adults**



# Typhoid vaccines

- **Oral Ty21a**

**4 capsules over 1 week**


**Repeat every 5yrs**

**Production restarted**

- **Vi Polysaccharide**

**>2 yrs old**

**Repeat every 2 -3 yrs**






# Japanese Encephalitis Vaccines

- **Ixiaro<sup>®</sup>** ( Inactivated, cell culture derived)
  - 2mo - 2 yrs : 0.25 ml IM ; 0 & 28 days
  - >2 yrs : 0.5 ml IM (same as adults) “
  - Booster- data only on >17 yo



- **Indications**
  - 1 month in endemic area during transmission season



## What vaccines would be appropriate for this 5 month old?

0

A Yellow Fever

0%

B MMR

0%

C Typhoid

0%

D DTaP-IPV-HepB

0%

E Rabies

0%

None of the above

0%

# Practical issues

- **Vaccine site**
  - Vastus lateralis/deltoid
- **Calm, confident manner**
- **Reasoning – tends not to work!**
- **Distraction**
  - Bubbles, ipod/ipad/headphones
- **Positioning**
- **Rewards**
  - Special treat, praise



Photo courtesy of Clare Shaw



# Malaria prevention A-B-C-Ds

(and dengue/chikungunya/tick disease)

- ▶ **A**wareness of risk
- ▶ **B**ite prevention
- ▶ **C**hemoprophylaxis
- ▶ **D**iagnosis



# Malaria chemoprophylaxis –Which drug?


- ▶ Chloroquine
- ▶ Mefloquine
- ▶ Atovaquone/Proguanil
- ▶ Doxycycline
- ▶ Primaquine




# Does this breastfeeding infant need malaria chemoprophylaxis?

0


A Yes




B No- Mom will be on medications



C I'm not sure



None of the above





# Breastfeeding travelers

- **Little data**

- **Medications**

Check for breast milk excretion & infant side effects

- **Anti-malarials**

All transfer to breast milk but insufficient amount for infant

A/P contraindicated in mom if infant is <5 kg

Doxycycline OK for short-term use

PQ OK if both have normal G6PD level

- **Vaccines**

Generally no contraindications except YF precaution





- **“Neither inactivated nor live-virus vaccines administered to a lactating woman affect the safety of breastfeeding for women or their infants” ACIP**
- **YF precaution -contraindicated unless high risk of disease**
- **Mpox (ACAM2000) and smallpox vaccines are contraindicated**
- **Jynneos (replication deficient Mpox vaccine) can be given if indicated.**



# Breastfeeding & travel



- **Transport through airport security**
- **Breast care - avoiding/treating mastitis**
- **Breast pump - batteries, hand pump, electric**
- **Pumped milk - safe for 4 hrs at room temp**

# Unique considerations for families

beyond vaccines and anti-malarials...

**Age specific issues**

**Safety**

**Logistics**

**Teen/student issues**

**Comfort issues**

**Stress/boredom**

**Environmental hazards**

**Altitude**

**Sedation requests**







# Travelers diarrhea →




Figure 1. Incidence rate per month of VPDs in travellers; best estimate for non-immunes

# Definitions of Travelers' Diarrhea

- *Journal of Travel Medicine*, 2017, Vol 24, Suppl 1.



|               |  |  |  |                          |
|---------------|--|--|--|--------------------------|
| Pre-travel    | <p><b>Providers should consider the following in counseling the traveler:</b></p> <ol style="list-style-type: none"> <li>(1) Definitions of travelers' diarrhea and severity classification</li> <li>(2) Importance of oral rehydration through fluid and salt intake for all travelers' diarrhea</li> <li>(3) Information on effectiveness of treatments for travelers' diarrhea and the risk of travel, travelers' diarrhea, and antibiotic use with the acquisition of multi-drug resistance bacteria.</li> <li>(4) Provision of empiric treatment medications as indicated by itinerary and provider-traveler determination</li> <li>(5) Intra- and post-travel illness follow-up recommendations</li> </ol> |  |  |                          |
| During Travel | <p><b>Self-determination of Illness Severity</b></p>   |  |  |                          |
|               | <p><b>Mild</b></p> <p>Diarrhea that is tolerable, is not distressing, and does not interfere with planned activities</p>   | <p><b>Moderate</b></p> <p>Diarrhea that is distressing or interferes with planned activities</p> | <p><b>Severe</b></p> <p>Diarrhea that is incapacitating or prevents planned activities</p> |                          |
|               |  |  | <p><b>Non-dysentery</b></p>  | <p><b>Dysentery*</b></p> |
|               | <p><u>May</u> use loperamide or bismuth subsalicylates</p>   | <p><u>May</u> use loperamide alone or as an adjunct to antibiotics</p>                           | <p><u>May</u> use loperamide as adjunct to antibiotics</p>                                 |                          |
|               |  | <p>±</p>   | <p>+</p>   |                          |
|               | <p><u>May</u> use antibiotic (Table 2)</p>   |  | <p><u>Should</u> use antibiotic (Table 2)</p>  |                          |
| Post-travel   | <p>Acute travelers' diarrhea should be treated empirically as above.</p>   |  |  |                          |
|               | <p>Microbiologic testing is recommended in returning travelers with severe or persistent symptoms or in those who fail empiric therapy</p>   |  |  |                          |
|               | <p>Multiplex molecular diagnostics are preferred in patients with persistent or chronic symptoms</p>   |  |  |                          |





# Case 2

- 38yo, G2P1 , grew up in Kenya until the age of 22
- 21 wks pregnant
- Plans travel home to Kenya to visit friends and relatives for 6 weeks
- Itinerary includes Nairobi and Mombasa
- Has had malaria several times and believes herself immune
- No vaccines since age 15





# Pre-travel issues

- **COVID19**
- **Advisability of the trip**
- **Airline requirements**
- **In-flight considerations**
- **Medical care**



# Travel & pregnancy : contraindications

- **Complicated pregnancy**
- **Hypertension**
- **History of pre-term labor**
- **Diabetes**
- **Cardiac disease**
- **History of intrauterine growth restriction**



# Scuba Diving

- **Unsafe at any stage of pregnancy**
- **Risk of fetal decompression sickness**

# Cruise Travel


- **COVID19**
- **Cruise line restrictions- 24-28 wks**
- **Medical concerns (GI illness)**



# Zika in Pregnancy

- **Outbreak 2016, decline since**
- **Postpone travel if outbreak**
- **US Zika Pregnancy Registry**
- **First trimester highest risk**
  - Up to 15 % birth defects
  - Microcephaly, Eye abnormalities**

World Map of Areas with Risk of Zika



Map Legend


- Area with risk of Zika infection (below 6,500 feet)\*
- Area with low likelihood of Zika infection (above 6,500 feet)\*
- Areas with no known risk of Zika infection





# Immunizations & pregnancy

- **If essential**
  - AVOID 1<sup>st</sup> trimester**
  - AVOID live viral vaccines, except in special circumstances (YF)**
- **No evidence that bacterial, inactivated viral, toxoids, or tetanus immune globulin pose risk to fetus**
- **Consider letter of waiver**



# Vaccination & pregnancy

- **Routine**

  - Tetanus/diphtheria/acellular pertussis - @27-36 wks

  - Influenza

- **Recommended as indicated**

  - COVID-19**

  - Hepatitis A**

  - Rabies**

  - Insufficient data on JEV**

  - Polio (inactivated)**

  - Hepatitis B**

  - Inj typhoid**

# Vaccination in Pregnancy

## Recommended (Safe)

- Influenza (inactivated)
- Tdap
- COVID-19

## Recommended if otherwise indicated (Safe)


- Hepatitis B
- Hepatitis A
- dT
- Polio(IPV)
- Rabies
- Polysaccharide meningococcal MPSV4, MenACYW
- Immunoglobulins (RIG, VZIG)

## If benefit outweighs risk (Probably safe)

- Yellow fever
- Typhoid (Ty21a)
- Japanese encephalitis (inactivated)


## Contraindicated (Theoretical Risk)

- MMR
- Varicella, Zoster
- LAIV (Influenza)
- BCG
- Oral typhoid vaccine
- Live attenuated Japanese Encephalitis






# YF vaccine & pregnancy

- Postpone travel if possible
- Safety not established, can give if travel is unavoidable, risk warrants
- Early studies suggested possible  abortion risk - not reproduced
- If used, booster dose is indicated <sup>1</sup>
- Transmitted in breastmilk- 3 cases

1. MMWR June 19, 2015 / 64(23);647-650



# Vaccination in Pregnancy

|                | Vaccine                    | General Recommendation for Use in Pregnant Women                                |
|----------------|----------------------------|---|
| Routine        | Hepatitis A                | May be used if benefit outweighs risk.  |
|                | Hepatitis B                | Recommended in some circumstances.  |
|                | Human Papillomavirus (HPV) | Not recommended.  |
|                | Influenza (Inactivated)    | Recommended.  |
|                | Influenza (LAIV)           | Contraindicated.  |
|                | MMR                        | Contraindicated.  |
|                | MCV4                       | Inadequate data for specific recommendation.                                    |
|                | PCV13                      | Inadequate data for specific recommendation.                                    |
|                | PPSV23                     | Inadequate data for specific recommendation.                                    |
|                | Polio                      | May be used if needed.  |
|                | Td                         | Should be used if otherwise indicated.  |
|                | Tdap                       | Should be used if otherwise indicated.  |
|                | Varicella                  | Contraindicated.  |
|                | Zoster                     | Contraindicated.  |
| Travel & Other | Anthrax                    | Low risk of exposure – not recommended.<br>High risk of exposure – may be used. |
|                | BCG                        | Contraindicated.  |
|                | Japanese Encephalitis      | Inadequate data for specific recommendation.                                    |
|                | Meningococcal (MPSV4)      | May be used if otherwise indicated.   |
|                | Rabies                     | May be used if otherwise indicated.   |
|                | Typhoid                    | Inadequate data for specific recommendation.                                    |
|                | Smallpox                   | Pre-exposure – contraindicated.<br>Post-exposure – recommended.                 |
|                | Yellow Fever               | May be used if benefit outweighs risk.  |

| VACCINE/IMMUNOBIOLOGIC  | TYPE  | USE   |
|---|---|---|
| Immune globulins, pooled or hyperimmune   | Immune globulin or specific globulin preparations | If indicated for pre- or postexposure use. No known risk to fetus   |
| <b>Vaccination of pregnant women is recommended</b>   |   |   |
| Hepatitis B   | Recombinant or plasma-derived                     | Recommended for women at risk of infection  |
| Influenza <sup>1</sup>  | Inactivated whole virus or subunit                | All people >6 months, including women who will be or are pregnant during the flu season (September–March), regardless of trimester, and women at high risk for pulmonary complications, regardless of trimester   |
| Tetanus-diphtheria (Td)   | Toxoid  | If indicated, such as lack of primary series or no booster within past 10 years   |
| Tetanus-diphtheria-pertussis (Tdap)   | Toxoid, acellular                                 | Not contraindicated, but no data are available on safety, immunogenicity, and outcomes of pregnancy. ACIP recommends Td when tetanus and diphtheria protection are required but Tdap to add protection against pertussis in some situations. Second or third trimester is preferred.  |
| Hepatitis A   | Inactivated virus                                 | No data are available on safety in pregnancy. Because hepatitis A vaccine is produced from inactivated hepatitis A virus, the theoretical risk of vaccination should be weighed against the risk of disease. Consider immune globulin rather than vaccine.  |
| <b>Pregnancy is a Precaution, and Under Normal Circumstances, Vaccination Should Be Deferred; Vaccine Should Only Be Given when Benefits Outweigh Risks</b> |   |   |
| Japanese encephalitis   | Inactivated virus                                 | No data are available on safety in pregnancy. Pregnant women who must travel to an area where the risk is high should be vaccinated when the theoretical risks are outweighed by the risk of disease.   |
| Meningococcal meningitis  | Polysaccharide                                    | Meningococcal conjugate vaccine (MenACWY) is preferred for adults; however, no data are available on safety and immunogenicity in pregnant women. Meningococcal polysaccharide vaccine (MPSV4) can be administered during pregnancy if the woman is entering an epidemic area. Indications for prophylaxis are not altered by pregnancy; vaccine is |

**A 32 yr old G1P0 woman 18 weeks pregnant seeks advice and vaccination for a 2 wk trip to Costa Rica in 4 weeks**

**Two brief episodes of first trimester bleeding**

**Ultrasound - normal placenta**

**8 hr flight**

**Staying in small hotels in cities**



## What advice can you give this traveler?

0

A Discuss the advisability of the trip with the OB provider

0%

B Updating vaccines with Hepatitis A and possibly Typhoid is advised

0%

C Insect repellent can be safely used

0%

D Scuba diving is contraindicated

0%

E Purchase evacuation insurance and carry OB records

0%

All of the above

0%



**A mom is traveling to her family's home in Delhi to spend three months. She is breastfeeding her 6 mo old.**

**Which of the following can you tell her?**

- a. The baby won't need an anti-malarial if mom takes one**
- b. Breast pumps are not permitted on planes**
- c. She can receive the needed vaccines**
- d. All of the above**





# Case 3

- **A 23 yr old with Crohn's disease for 15 years is planning a trip to South America for 2 months. She is on 10 mg Prednisone per day and has been on Humira for 10 years.**
- **A 44 yr old male is status post kidney transplant 3 yrs ago and taking a trip to Morocco to visit relatives. He is on Cellcept and has had a good year, after having a rejection episode 18 mo ago**





# Biologics

- **Variable effect on the immune system**
- **All cause a degree of immune suppression that has impact on vaccine response and adverse events**
  
- **<https://www.fda.gov/vaccines-blood-biologics/licensed-biological-products-supporting-documents>**





# FDA approved biologics

|                               | Route | Rheumatoid Arthritis | Plaque Psoriasis | Psoriatic Arthritis | Ankylosing Spondylitis | Juvenile Idiopathic Arthritis | Crohn's Disease | Ulcerative Colitis |
|-------------------------------|-------|----------------------|------------------|---------------------|------------------------|-------------------------------|-----------------|--------------------|
| Abatacept (Orencia®)*         | SC,IV | X                    |                  |                     |                        | X                             |                 |                    |
| Adalimumab (Humira®)*         | SC    | X                    | X                | X                   | X                      | X                             | X               | X                  |
| Anakinra (Kineret®)*          | SC    | X                    |                  |                     |                        |                               |                 |                    |
| Certolizumab pegol (Cimzia®)* | *SC   | X                    |                  |                     |                        |                               | X               |                    |
| Etanercept (Enbrel®)*         | SC    | X                    | X                | X                   | X                      | X                             |                 |                    |
| Golimumab (Simponi®)*         | SC    | X                    |                  | X                   | X                      |                               |                 |                    |
| Infliximab (Remicade®)        | IV    | X                    | X                | X                   | X                      |                               | X               | X                  |
| Rituximab (Rituxan) #         | IV    | X                    |                  |                     |                        |                               |                 |                    |
| Tocilizumab (Actemra®)        | IV    | X                    |                  |                     |                        | X                             |                 |                    |
| Ustekinumab (Stelara®)*       | SC    |                      | X                |                     |                        |                               |                 |                    |
| Tofacitinib (Xeljanz®)**      | Oral  | X                    |                  |                     |                        |                               |                 |                    |

\*SC injectable products allow for patient self-administration

\*\*First oral biologic available in US for rheumatoid arthritis

# Rituximab is also indicated as an antineoplastic.

# Some caveats

- **All immunocompromised patients traveling outside of Europe, N America, Australia/New Zealand, Caribbean resorts are best seen in a Travel Medicine Clinic**
- **Time since transplant:**
  - **>1 year after organ transplant**
  - **> 2 years after stem cell transplant**
  - **no recent complications, on lower immunosuppression\***
- **<https://wwwnc.cdc.gov/travel/destinations/list>**



# Vaccinating the traveler : 3 Rs

## **R**outine vaccines

**Esp measles, polio & COVID-19**

## **R**equired vaccines

*Yellow fever*

**Meningococcal meningitis (Hajj)**

## **R**ecommended



# Table 2 Recommended Adult Immunization Schedule by Medical Condition or Other Indication, United States, 2024

Always use this table in conjunction with Table 1 and the Notes that follow. Medical conditions or indications are often not mutually exclusive. If multiple medical conditions or indications are present, refer to guidance in all relevant columns. See Notes for medical conditions or indications not listed.

| VACCINE      | Pregnancy                          | Immunocompromised (excluding HIV infection)         | HIV infection CD4 percentage and count |                 | Men who have sex with men            | Asplenia, complement deficiency | Heart or lung disease | Kidney failure, End-stage renal disease or on dialysis | Chronic liver disease; alcoholism* | Diabetes | Healthcare Personnel <sup>b</sup> |
|--------------|------------------------------------|---|--|-----------------|--------------------------------------|---------------------------------|-----------------------|--|------------------------------------|----------|-----------------------------------|
|              |                                    |   | <15% or <200mm                         | ≥15% and ≥200mm |                                      |                                 |                       |  |                                    |          |                                   |
| COVID-19     |                                    | See Notes   |  |                 |                                      |                                 |                       |  |                                    |          |                                   |
| IIV4 or RIV4 |                                    | 1 dose annually                                     |  |                 |                                      |                                 |                       |  |                                    |          |                                   |
| LAIV4        |                                    | 1 dose annually if age 19 - 49 years                |  |                 | 1 dose annually if age 19 - 49 years |                                 |                       |  |                                    |          |                                   |
| RSV          | Seasonal administration. See Notes | See Notes   |  | See Notes       |                                      |                                 |                       |  |                                    |          |                                   |
| Tdap or Td   | Tdap: 1 dose each pregnancy        | 1 dose Tdap, then Td or Tdap booster every 10 years |  |                 |                                      |                                 |                       |  |                                    |          |                                   |
| MMR          | *                                  |   |  |                 |                                      |                                 |                       |  |                                    |          |                                   |
| VAR          | *                                  | See Notes   |  |                 |                                      |                                 |                       |  |                                    |          |                                   |
| RZV          |                                    | See Notes   |  |                 |                                      |                                 |                       |  |                                    |          |                                   |
| HPV          | *                                  | 3 dose series if indicated                          |  |                 |                                      |                                 |                       |  |                                    |          |                                   |
| Pneumococcal |                                    |   |  |                 |                                      |                                 |                       |  |                                    |          |                                   |
| HepA         |                                    |   |  |                 |                                      |                                 |                       |  |                                    |          |                                   |
| Hep B        | See Notes                          | Age ≥ 60 years                                      |  |                 |                                      |                                 |                       |  |                                    |          |                                   |
| MenACWY      |                                    |   |  |                 |                                      |                                 |                       |  |                                    |          |                                   |
| MenB         |                                    |   |  |                 |                                      |                                 |                       |  |                                    |          |                                   |
| Hib          |                                    | HSCT: 3 doses <sup>c</sup>                          |  |                 | Asplenia: 1 dose                     |                                 |                       |  |                                    |          |                                   |
| Mpox         | See Notes                          | See Notes   |  |                 |                                      | See Notes                       |                       |  |                                    |          |                                   |

  Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity  
  Recommended based on shared clinical decision-making  
  Not recommended for all adults, but recommended for some adults based on either age OR increase in risk for or severe outcomes from disease  
  Recommended for all adults, and additional doses may be necessary based on medical condition or other indications. See Notes.  
  Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction  
  Contraindicated or not recommended \*Vaccinate after pregnancy, if indicated  
  No Guidance/ Not Applicable

a. Precaution for LAIV4 does not apply to alcoholism.      b. See notes for influenza; hepatitis B; measles, mumps, and rubella; and varicella vaccinations.      c. Hematopoietic stem cell transplant.



# Vaccine Types

## Live

Rotavirus  
JE (Imojev)  
OPV  
MMR  
YF  
VZV  
Oral Typhoid  
Dengue

## Inactivated

DTaP,DT, dT  
IPV  
Hep A  
Rabies  
TBE  
JE  
Shingles  
Influenza

## Subunit, Recombinant, Polysaccharide, Conjugate

Hep B  
HiB  
PPV23  
PCV13,15,20  
Meningococcal  
HPV  
Inj Typhoid

## Toxoid

Tetanus  
Diphtheria

## Viral vector, mRna COVID19

# Precautions with live vaccines

- **Not safe for certain populations (immunosuppressed, pregnant women)**
- **Circulating antibody can interfere with response**
- **Fragile – careful storage and handling**



# Yellow Fever vaccine

## Contraindications

Age <6 mo

Egg/gelatin allergy

Immune suppression

Immune modulators

Organ transplantation

Thymus disorders

Malignant neoplasms

## Precautions

Age 6-8 mo

Age > 60 yo

Pregnancy

Breastfeeding

Asymptomatic HIV

<https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/yellow-fever>



# Measles vaccine?





# Measles vaccine?

**Table 2** Recommended Adult Immunization Schedule by Medical Condition or Other Indication, United States, 2024

Always use this table in conjunction with Table 1 and the Notes that follow. Medical conditions or indications are often not mutually exclusive. If multiple medical conditions or indications are present, refer to guidance in all relevant columns. See Notes for medical conditions or indications not listed.

| VACCINE      | Pregnancy                          | Immunocompromised (excluding HIV infection)         | HIV infection CD4 percentage and count |                 | Men who have sex with men            | Asplenia, complement deficiency | Heart or lung disease                | Kidney failure, End-stage renal disease or on dialysis | Chronic liver disease; alcoholism <sup>a</sup> | Diabetes | Healthcare Personnel <sup>b</sup> |
|--------------|------------------------------------|---|--|-----------------|--------------------------------------|---------------------------------|--------------------------------------|--|--|----------|-----------------------------------|
|              |                                    |   | <15% or <200mm                         | ≥15% and ≥200mm |                                      |                                 |                                      |  |  |          |                                   |
| COVID-19     |                                    | See Notes   |  |                 |                                      |                                 |                                      |  |  |          |                                   |
| IIV4 or RIV4 |                                    | 1 dose annually                                     |  |                 |                                      |                                 |                                      |  |  |          |                                   |
| LAIV4        |                                    |   |  |                 | 1 dose annually if age 19 - 49 years |                                 | 1 dose annually if age 19 - 49 years |  |  |          |                                   |
| RSV          | Seasonal administration. See Notes | See Notes   |  |                 |                                      |                                 | See Notes                            |  |  |          |                                   |
| Tdap or Td   | Tdap: 1 dose each pregnancy        | 1 dose Tdap, then Td or Tdap booster every 10 years |  |                 |                                      |                                 |                                      |  |  |          |                                   |
| MMR          | *                                  |   |  |                 |                                      |                                 |                                      |  |  |          |                                   |
| VAR          | *                                  | See Notes   |  |                 |                                      |                                 |                                      |  |  |          |                                   |
| RZV          |                                    | See Notes   |  |                 |                                      |                                 |                                      |  |  |          |                                   |
| HPV          | *                                  | 3 dose series if indicated                          |  |                 |                                      |                                 |                                      |  |  |          |                                   |
| Pneumococcal |                                    |   |  |                 |                                      |                                 |                                      |  |  |          |                                   |
| HepA         |                                    |   |  |                 |                                      |                                 |                                      |  |  |          |                                   |
| Hep B        | See Notes                          |   |  |                 |                                      |                                 | Age ≥ 60 years                       |  |  |          |                                   |
| MenACWY      |                                    |   |  |                 |                                      |                                 |                                      |  |  |          |                                   |
| MenB         |                                    |   |  |                 |                                      |                                 |                                      |  |  |          |                                   |
| Hib          |                                    | HSCT: 3 doses <sup>c</sup>                          |  |                 |                                      | Asplenia: 1 dose                |                                      |  |  |          |                                   |
| Mpox         | See Notes                          |   |  |                 | See Notes                            |                                 | See Notes                            |  |  |          |                                   |

  Recommended for all adults who lack documentation of vaccination, OR lack evidence of immunity  
  Not recommended for all adults, but recommended for some adults based on either age OR increased risk for or severe outcomes from disease  
  Recommended based on shared clinical decision-making  
  Recommended for all adults, and additional doses may be necessary based on medical condition or other indications. See Notes.  
  Precaution: Might be indicated if benefit of protection outweighs risk of adverse reaction  
  Contraindicated or not recommended  
  No Guidance/ Not Applicable  
<sup>a</sup>Precaution for LAIV4 does not apply to alcoholism.      <sup>b</sup>See notes for influenza; hepatitis B; measles, mumps, and rubella; and varicella vaccinations.      <sup>c</sup>Hematopoietic stem cell transplant.





**Advice?**



- **Contingency plans**
- **Communications with home team**
- **Itinerary adjustment to avoid high risk situations**
- **Trip/medical/evacuation insurance**


# Traveling with chronic conditions

- **Medication supply**
- **Evacuation insurance**
- **Contingency plans**
- **Medical records**
- **In-flight needs**
- **IAMAT ( International Association for Medical Assistance to Travelers)**





# Summary & Conclusions





# Vaccinating the traveler : 3 Rs

## **R**outine vaccines

**Esp measles, polio & COVID-19**

## **R**equired vaccines

*Yellow fever*

**Meningococcal meningitis (Hajj)**

## **R**ecommended





# Summary- child travelers

- **Be aware of safety issues**
- **Travel with a medical kit**
- **Carry ORS packets & know how to handle diarrhea when traveling**
- **Consider rx of Azithromycin (10mg/kg/day) x 3 days, unreconstituted, to use if severe diarrhea occurs**
- **Excellent resource for parents**  
**<https://www.healthychildren.org> symptom checker**

# Summary - pregnant travelers


- **Use all resources (advice, practical tips, medications & vaccines) to help your traveler prevent disease**
- **Virtually all medications and vaccines are less harmful than the diseases they prevent or treat**
- **The likeliest problems in a pregnant traveler are not vaccine preventable – diarrhea and DVT**





# Summary- Immunocompromised

- **Be familiar with the definitions of differing immune compromise**
- **Read CDC Yellow Book Chapter on Immunocompromised travelers**
- **Help assess itinerary, timing, risk and benefits**
- **Update routine & travel vaccines**
- **Recognize risks of live vaccines in immune compromised travelers**
- **Assess drug interactions if prescribing for travelers diarrhea or malaria prevention**



# Road Safety

- Hire a car with a local professional driver rather than driving
- Check the tires, brakes, lights and safety belts and child safety straps on rental cars
- Wear safety belts in vehicles
- **Do not use motorbikes, wear a helmet**
- Use alcohol responsibly , avoid drug use
- Be aware of local traffic patterns if walking or cycling
- Avoid night travel



# Promoting Healthy and Safe Travel

[Our Mission](#)



## Who We Are & What We Do

The ISTM is the largest organization of professionals dedicated to the advancement of the specialty of travel medicine. Focused on the prevention and management of health problems related to international travel and migration, members include physicians, nurses, pharmacists and other health professionals from academia, government and the private sector. ISTM invites all who are interested in travel medicine to join and participate in the advancement of this field.

[Learn More](#)









# Selected resources

- **Join ISTM! International Society of Travel Medicine [www.istm.org](http://www.istm.org)**
- **General: Keystone, et al: Travel Medicine ,4<sup>th</sup> Ed.**
- **CDC Yellow Book 2024**
- **[Cdc.gov/travel](http://Cdc.gov/travel)**
- **Am Acad Pediatrics Red Book 2021-2024**
- **<https://www.immunize.org/vaccines/>**
- **International Association for Medical Assistance to Travelers: [www.iamat.org](http://www.iamat.org)**

# Selected resources: Pregnancy

- **General: CDC Yellow Book 2024**  
Keystone, et al : Travel Medicine, 4<sup>th</sup> Ed. 2018; Chapter 22
- **YF vaccination** Vaccine 2006 Feb 27;24(9):1421-6
- **Air travel** Magann EF<sup>1</sup>, et al ;Travel and pregnancy outcomes: a review of pregnancy regulations and outcomes for passengers, flight attendants, and aviators. Obstet Gynecol Surv. 2010 Jun;65(6):396-402.  
ACOG Committee Opinion No. 746: Air travel during pregnancy:Obstetrics & Gynecology: [August 2018 - Volume 132 - Issue 2 - p e64–e66](#)  
Nicholas JS, et al. Aviat Space Environ Med 2000 Jun;71(6):647-8
- **DVT: Lindqvist P, et al. Obstet Gynecol 1999;94:730-734**  
Cannegieter SC et al .Pregnancy and travel-related thromboembolism. [Thromb Res.](#) 2013 Jan;131 Suppl 1:S55-8.  
Morteza Izadi,et al ; Do pregnant women have a higher risk for venous thromboembolism following air travel? Adv Biomed Res. 2015; 4: 60.
- **Vaccines** CDC. Guidelines for vaccinating pregnant women. Atlanta: CDC; 2024
- **Altitude:** <https://www.theuiaa.org/mountaineering/advice-for-women-going-to-altitude/>
- **Zika:** <https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2019/09/management-of-patients-in-the-context-of-zika-virus>
  - <https://www.who.int/ith/updates/20170310/en/>

